Skip to main content

Table 1 Basic characteristics of included studies

From: Efficacy of transversus abdominis plane block for gastric surgery: a meta-analysis

Study

Year

Country

Sample size

Gender(Male/Female)

Mean age

Intervention

Injection method

Surgical method

Outcome

EG

CG

EG

CG

EG

CG

A. Aboseif

2023

Egypt

20

20

8/32

41

40

TAP

Placebo

Ultrasound-guided

LGB; LSG

NRS; F1;F4;F5;F6;F7;F8;F9

A. M. Said

2017

USA

45

45

31/59

32

33

TAP

Morphine

Laparoscopically assisted

LSG

NRS; F9;F10;F12;F14

B.M.Abdelhamid

2020

Egypt

22

22

25/19

36

36

TAP

Opioid

Ultrasound-guided

LSG

VAS; F18;F19;F20;F21

E. Albrecht

2013

USA

27

30

11/46

45

39

TAP

Placebo

Ultrasound-guided

LGB

NRS; F22;F23;F24

G. Okut

2022

Turkey

30

30

28/32

35

32

TAP

Placebo

Laparoscopically assisted

LSG

VAS; F27;F28

J. Ruiz-Tovar

2018

Spain

70

70

60/80

42

42

TAP

PSI

Laparoscopically assisted

RYGB

VAS; F28;F29;F30

K. A. Wong

2020

USA

75

71

22/124

42

40

TAP

Placebo

Laparoscopically assisted

LSG; RYGB

F0;F12;F24;F26;F32

R. Liu

2019

China

30

31

44/17

59

60

TAP

Placebo

Ultrasound-guided

Open radical gastrectomy

VAS; F38;F33;F34;F9;F12;F39

R. M. Hussien

2023

Egypt

15

15

15/15

41

41

TAP

NSAIDS

Ultrasound-guided

LSG

VAS; F33;F19

T. Mittal

2018

India

30

30

N/A

N/A

N/A

TAP

Placebo

Ultrasound-guided

LSG

VAS; F12;F17;F10

W. Zhan

2020

China

30

30

30/30

58

60

TAP

Placebo

Ultrasound-guided

Open radical gastrectomy

VAS; F33

Y. Wu

2013

China

27

26

37/16

60

62

TAP

Placebo

Ultrasound-guided

Open radical gastrectomy

VAS; F9;F12

  1. EG: Experimental Group; CG: Control Group; TAP: Transversus Abdominis Plane; NRS: Numerical rating scale; VAS: Visual analogue scale; LGB: Laparoscopic gastric bypass; LSG: Laparoscopic sleeve gastrectomy; RYGB: Roux-en-Y Gastric Bypass; PSI: Port-site infiltration; F0: Pain score; F1: OR Time; F2: Blood Loss; F3: Pain Scores at three hours postoperatively; F4: FVC (L) after operation; F5: FEV1 (L) after operation; F6: FEV1/FVC (%) after operation; F7: PaO2 (mmHg) after operation; F8: PaO2/FiO2 after operation; F9: Morphine consumption (mg); F10: No. of requested doses of rescue analgesia; F12: Time to first ambulation, flatus (h); F14: Time to first oral intake (h); F17: Patient Satisfaction Score; F18: Paracetamol consumption (g); F19: Pethidine consumption (mg); F20: First request of rescue analgesia (h); F21: Total fentanyl requirement (µg); F22: Cumulative postoperative opioid consumption; F23: The time to first analgesic request; F24: Length of stay in hospital; F25: Mean arterial pressure (MAP); F26: PCA pump measurements; F27: Time to first flatus and defecation; F28: Length of hospital stay; F29: Morphine rescues (%); F30: Hospital discharge during the first 48 h after surgery (%); F31: Prophylaxis of nauseas and vomiting appeared (%); F32: Nonopioid pain medication usage; F33: Changes in SBP (mmHg), DBP (mmHg) and HR (beats/min) before and after skin incision; F34: The dose of sufentanil (µg), nicardipine (mg) and esmolol (mg) supplemented intraoperatively; F35: PACU morphine analgesia (mg); F36: Intraoperative rescue fentanyl; F37: The dose of propofol (mg), remifentanil (µg) supplemented intraoperatively; F38: Neuroendocrine mediators and cytokines at different time points of 48 h after operation; F39: PACU stay (min); F40: Extubation time; F41: Postoperative rescue fentanyl; F42: Tramadol consumption during the first day after surgery; F43: Prophylaxis of nauseas and vomiting appeared score; F44: Quality of Recovery Questionnaire 40; F45: Sedation scores; F46: The dose of sufentanil (µg), remifentanil (mg), Propofol (g), Oxymetazoline (µg), supplemented intraoperatively
Back to article page

BMC Anesthesiology

ISSN: 1471-2253

Contact us